Antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium isolates from the private healthcare sector in South Africa: A pilot study by Maduna, L D et al.
995       October 2021, Vol. 111, No. 10
RESEARCH
The increasing prevalence of antimicrobial resistance (AMR) in 
the sexually transmitted infections (STIs) Neisseria gonorrhoeae 
and Mycoplasma genitalium is a major concern worldwide.[1] In 
South Africa (SA), STIs are treated syndromically based on the 
patient’s presenting symptoms and using a combination of broad-
spectrum empirical antibiotics. The standard regimen for urethral 
and vaginal discharge syndrome is ceftriaxone and azithromycin 
with or without metronidazole.[2] An important limitation of the 
syndromic management approach is that there are limited data on 
the occurrence of AMR in N. gonorrhoeae and M. genitalium, owing 
to the lack of routine laboratory diagnostics.
The healthcare system in SA is two-tiered: the public healthcare 
sector provides free healthcare and serves the majority of the 
population (>80%), while private healthcare is accessed by the minority 
(15 - 17%) and is largely paid for through private health insurance. [3] 
Both sectors use syndromic treatment for STI management.[2] 
However, most of the AMR data have been reported from the public 
healthcare sector. The national STI sentinel surveillance is conducted 
only in public sector facilities, and research studies have focused on 
that sector as well.[4-7] Research on the occurrence of AMR in STIs in 
the private healthcare sector therefore remains limited.[8,9]
There are substantial differences between the private and 
public healthcare sectors with regard to patients’ healthcare-
seeking behaviour, antimicrobial drug prescribing practice, and 
socioeconomic status of the patient population.[10] These factors 
could all impact on the occurrence of antimicrobial-resistant STIs 
and result in different epidemiological profiles in the two sectors.
Objectives
To conduct a pilot study to determine the frequency of AMR of 
N. gonorrhoeae and M. genitalium in patients accessing SA’s private 
healthcare sector.
Methods
In this cross-sectional study, N. gonorrhoeae-positive cultures 
and M.  genitalium DNA samples with linked anonymous clinical 
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Background. Reports have emerged globally of antimicrobial resistance (AMR) in Neisseria gonorrhoeae and Mycoplasma genitalium 
infections. In South Africa (SA), there are substantial differences between private and public healthcare with regard to antimicrobial drug 
prescribing practice, which could affect AMR patterns of private and public healthcare patients.
Objectives. To perform a pilot study to determine the frequency of AMR of N. gonorrhoeae and M. genitalium in patients accessing SA’s 
private healthcare sector.
Methods. In this cross-sectional study, N. gonorrhoeae-positive cultures and M. genitalium DNA samples were collected from a private 
healthcare reference laboratory from August 2018 to August 2019. In N. gonorrhoeae-positive cultures, antimicrobial susceptibility testing 
was performed, followed by N. gonorrhoeae multiantigen sequence typing (NG-MAST) to determine genetic relatedness of the isolates. To 
determine macrolide and fluoroquinolone resistance rates, M. genitalium-positive samples were analysed by sequencing the 23S rRNA, gyrA 
and parC genes.
Results. Twenty-one N. gonorrhoeae- and 27 M. genitalium-positive specimens were included in this analysis. High rates of resistance were 
detected among gonococcal isolates, with 90% resistance to tetracycline, 86% to penicillin and 62% to ciprofloxacin, but no resistance 
to azithromycin, cefixime and ceftriaxone. NG-MAST revealed genetically diverse isolates with 83% novel NG-MAST sequence types. 
Macrolide and fluoroquinolone resistance-associated mutations were detected in 18.5% (n=5/27) and 7.4% (n=2/27) of M. genitalium 
strains, respectively.
Conclusions. We observed high frequencies of ciprofloxacin, penicillin and tetracycline resistance in N. gonorrhoeae and macrolide 
resistance-associated mutations in M. genitalium in private healthcare sector patients in SA. This finding highlights the need to use 
diagnostics for sexually transmitted infections and to include the private healthcare sector in antimicrobial surveillance and stewardship 
programmes.
S Afr Med J 2021;111(10):995-997. https://doi.org/10.7196/SAMJ.2021.v111i10.15714
996       October 2021, Vol. 111, No. 10
RESEARCH
information were collected from a private healthcare sector diag-
nostic reference laboratory in Pretoria, SA, from August 2018 to August 
2019. This reference laboratory receives specimens for pathology 
services from all provinces in SA. The laboratory uses New York 
City (NYC) agar to culture and matrix-assisted laser desorption/
ionisation time-of-flight mass spectrometry (MALDI-TOF MS; Bruker, 
USA) to identify N. gonorrhoeae, and the Anyplex II STI-7 assay 
(Seegene, Korea) to detect M. genitalium. Cultured N. gonorrhoeae and 
M.  genitalium DNA were transported to the Department of Medical 
Microbiology at the University of Pretoria for further resistance testing.
At the University of Pretoria, N. gonorrhoeae was confirmed by 
Gram stain, rapid oxidase test and API NH (bioMérieux, France). 
Minimum inhibitory concentration (MICs) were determined using 
E-tests (bioMérieux, France) on the GC-agar base (Oxoid, UK) for 
tetracycline, ciprofloxacin, penicillin G, azithromycin, ceftriaxone, 
cefixime and spectinomycin. MICs were interpreted according to the 
European Committee of Antimicrobial Susceptibility Testing break-
points, except for azithromycin, where epidemiological cut-off (ECOFF) 
values were used because no resistance breakpoints exist (http://www.
eucast.org). N.  gonorrhoeae ATCC 49266 strain was used as quality 
control. Molecular typing of gonococcal isolates was done using the 
N. gonorrhoeae multiantigen sequence typing (NG-MAST) as previously 
described.[11] Sequences were submitted to the NG-MAST database 
(http://www.ng-mast.net) for assignment of sequence types (STs).
The presence of M. genitalium DNA was confirmed using a 
validated real-time polymerase chain reaction (PCR) assay targeting 
the MgPa adhesin gene.[11] Macrolide drug resistance-associated 
mutations in the 23S rRNA gene were identified using real-time 
PCR assay coupled with melting curve analysis for detection of 
point mutations.[12] Samples with a temperature peak different from 
the wild-type strains were sequenced to confirm mutations in the 
23S rRNA gene.[13] Quinolone resistance-associated mutations were 
detected by sequencing of quinolone resistance-determining regions 
(QRDRs) of gyrA and parC genes in macrolide-resistant strains, 
as previously described.[13] Ethical approval was obtained from 
the Research Ethics Committee at the Faculty of Health Sciences, 
University of Pretoria (ref. nos 253/2017, 207/2018 and 171/2019).
Results
Twenty-one N. gonorrhoeae isolates were collected over the study 
period, 19 from urethral swabs and 2 from vaginal swabs. Gonococcal 
isolates showed high rates of resistance to tetracycline (n=19/21; 
90%), penicillin (n=18/21; 86%) and ciprofloxacin (n=13/21; 62%). 
All isolates were susceptible to the cephalosporins and spectinomycin; 
MICs for azithromycin were all below the ECOFF.
NG-MAST classified 21 isolates into 12 different STs; 10 (n=10/12; 
83%) of these STs have not been described previously. Seven (n=7/12) 
STs were identified as unrelated singletons. Frequent STs were 
ST3609 (n=3 isolates), ST6216 (n=2), a novel ST containing porB 
allele 1320 and tbpB allele 623 (n=4), and a novel ST containing porB 
allele 11132 and tbpB allele 136 (n=3).
M. genitalium was confirmed in 27/27 (100%) of DNA samples 
received; 21 were from male urine samples, 4 from vaginal swabs and 
2 from urethral swabs. Melting curve analysis of DNA identified five 
strains that had a different melting temperature (62 - 64.7°C) from 
the wild-type strain (69°C). Sequence analysis confirmed macrolide 
resistance-associated mutations in the 23S rRNA in 18.5% (n=5/27) of 
M. genitalium strains; an A-to-G transition was detected at nucleotide 
position 2071 in 3 strains and at position 2072 in 2 (Table 1). Various 
amino acid alterations were observed in the ParC and GyrA  of the 
QRDR; two strains had a Gln-132→Arg substitution in the GyrA and 
the other one had a silent mutation (A318G). In addition, one strain 
had a Ser83→Ile substitution in the ParC and a concurrent gryA 
mutation (Gln-132→Arg) that has been associated with moxifloxacin 
and sitafloxacin treatment failures. [12] One isolate had a novel Met-
55→Leu substitution in the ParC of unknown clinical significance. 
Coexistent macrolide and quinolone resistance-associated mutations 
were detected in 2 patients.
Discussion
This pilot study reports on antimicrobial-resistant N. gonorrhoeae 
and M. genitalium infections in patients accessing the private 
health care sector in SA. We demonstrated high rates of AMR in 
N. gonorrhoeae isolates for some of the previously used antibiotics and 
concurrent macrolide and quinolone resistance-associated mutations 
in some of the M. genitalium strains. Although specimen collection 
was done over a 1-year period in a large reference laboratory, the 
number of strains obtained was limited, highlighting that diagnostic 
testing for STIs is performed only on a small scale in the private 
healthcare sector.
High frequencies of tetracycline and ciprofloxacin resistance were 
detected for gonococcal isolates; these drugs have been extensively 
used in the syndromic management of STIs in SA in the past two 
decades.[2] These findings are consistent with national surveillance 
data and a recent study in KwaZulu-Natal Province showing high 
rates of resistance to these antimicrobials in the public sector. [7,4] In 
addition, a higher frequency of resistance to penicillin (89%) was 
observed in gonococcal isolates in our study compared with the 
national sentinel surveillance, which reports a penicillin resistance 
prevalence of 51%.[4] This finding may be explained by a higher 
consumption of amoxicillin and amoxicillin/clavulanic acid in the 
private healthcare sector for other unrelated infections such as 
respiratory tract infections.[14] We did not observe azithromycin 
resistance in this selected group of gonococcal isolates from the 
Table I. Macrolide resistance-associated mutations and fluoroquinolone resistance-associated amino acid changes in GyrA and 
ParC in Mycoplasma genitalium from private healthcare sector patients in South Africa
Patient no. Province Gender Specimen type 23SrRNA* mutation
Amino acid change*
GyrA ParC
1 Western Cape M Urine A2071G Wild type Wild type
2 Western Cape M Urine A2071G Gln-132→Arg Met-55→Leu
3 Gauteng M Urine A2072G Wild type Wild type
4 Gauteng M Urethral swab A2072G Silent mutation† Wild type
5 Gauteng M Urethral swab A2071G Gln-132→Arg Ser83→Ile
M = male.
*Nucleotide positions or amino acid changes numbering according to M. genitalium G37 genome (NC_000908.2).
†Silent mutation (A318G).
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private healthcare sector, which is somewhat unexpected as there 
are concerns about emerging azithromycin resistance in the public 
healthcare sector.[7] Molecular epidemiological analysis of the 
gonococcal isolates showed genetic diversity, with a high number of 
novel NG-MAST STs that have not been described elsewhere.
A high frequency of macrolide resistance-associated mutations 
was detected in M. genitalium strains; this is in stark contrast to 
data from the public sector, where a low prevalence of macrolide 
resistance-associated mutations has been reported in several 
studies. [5,6,15] The observed high rate of macrolide resistance in the 
private healthcare sector could be due to selection bias, i.e. patients 
with urethritis not responding to empirical treatment may be more 
likely to have a diagnostic test. It could also result from different 
prescribing behaviour; azithromycin is commonly used for treatment 
of respiratory infections in the private healthcare sector, but not in 
the public sector.[14] Of concern is that we detected M. genitalium 
strains with coexistent macrolide and quinolone resistance-associated 
mutations in two patients.
Study limitations
This pilot study has several limitations. First, the relatively small 
sample size and geographical spread may not be fully representative 
of the population in the private sector; however, it does give an 
important insight into the situation and highlights the need for 
further research. Second, there was probably selection bias of patients 
who had specimens sent for laboratory diagnostics, as these are 
expensive, patients can generally not afford such tests, and syndromic 
treatment remains the cornerstone of STI management. Lastly, the 
therapeutic outcomes of the patients with dual-class resistance in 
M. genitalium associated with treatment failures were not available 
owing to the anonymised study design.
Conclusions
High frequencies of AMR in N. gonorrhoeae and macrolide resistance 
in M. genitalium were detected from patients in the private healthcare 
sector. This study highlights the importance of introducing routine 
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